Highlights d Two functional isoforms of the E protein factor are expressed in pDCs 
In Brief
The development of plasmacytoid dendritic cells is driven by E protein transcription factor TCF4 (E2-2). Grajkowska et al. show that TCF4 itself is controlled by multiple mechanisms including isoform-specific expression and positive feedback regulation through distal regulatory elements.
INTRODUCTION
E proteins are basic helix-loop-helix (bHLH) transcription factors that are orthologous to the Daughterless protein in Drosophila and in vertebrates include three proteins: TCF3 (E2a), TCF4 (E2-2), and TCF12 (HEB) (Kee, 2009; Murre, 2005) . E proteins bind their cognate DNA sequence termed ''E box'' (CANNTG) as homo-or heterodimers, and can either activate or repress their target genes. DNA binding by E proteins is antagonized by the Inhibitor of differentiation (Id) proteins that sequester E proteins into non-functional heterodimers. The net balance between E and Id proteins determines several key cell fate choices in the immune system (Rothenberg, 2014) , such as B cell versus natural killer (NK) cell specification (Boos et al., 2007) , the choice between CD4 + and CD8 + T cell lineages (Jones-Mason et al., 2012) , and peripheral T cell differentiation (Omilusik et al., 2013; Shaw et al., 2016) .
Full-length E proteins contain two canonical activation domains (AD1 and AD2), a TFIID-interacting activation domain (AD3) (Chen et al., 2013) , and the PCET and DES domains that mediate binding to the ETO family of transcriptional cofactors (Guo et al., 2009) . TCF3 has two splicing isoforms (E47 and E12), which play both unique and overlapping roles in B cell development (Beck et al., 2009 ). TCF12 comprises distinct transcriptional isoforms, including the AD1-containing ''canonical'' isoform and the AD1-lacking ''alternative'' isoform, which differ in their expression and function in reconstitution assays Wang et al., 2010) . Similarly, the AD1-containing ''long'' isoforms of TCF4 show stronger activation of a transcription reporter (Corneliussen et al., 1991; Sepp et al., 2011; Skerjanc et al., 1996) . The mechanisms of lineage-specific E protein activity, including the potential role of distinct E protein isoforms and the regulation of E protein expression, remain poorly understood.
Plasmacytoid dendritic cells (pDCs) comprise a distinct lineage specialized in the production of type I interferon (IFNa/b) in response to viruses and other pathogens. The features and genetic makeup of pDCs are highly conserved between humans and mice, reflecting an important role in immunity (Reizis et al., 2011; Swiecki and Colonna, 2015) . pDCs develop in the bone marrow (BM) from a common dendritic cell progenitor (CDP), which also gives rise to antigen-presenting classical dendritic cells (cDCs) (Schraml and Reis e Sousa, 2015; Shortman et al., 2013) . CDP-derived cDC progenitors (pre-DCs) differentiate into two main cDC subsets, CD8 + (CD103 + in tissues) and CD11b + (''myeloid''). These subsets are conserved in evolution and have been recently termed DC1 and DC2, respectively (Guilliams et al., 2014) . In addition to common origins, pDCs and cDCs share related gene expression profiles, dependence on the cytokine Flt3 ligand (Flt3L), and joint regulation by transcription factors including PU.1 and IRF8 (Merad et al., 2013; Satpathy et al., 2012) . Importantly, clonogenic CDPs can give rise to both pDCs and cDCs when cultured with Flt3L in the absence of any additional signals. This fact suggests that the pDC versus cDC lineage split is mediated by cell-intrinsic transcriptional mechanisms, such as feedback loops between lineage-specifying transcription factors. An important regulator of pDC development is the E protein TCF4. Tcf4 À/À mice show normal development of all immune cell types but lack pDCs, whereas Tcf4 +/À mice and human patients with TCF4 haplodeficiency (Pitt-Hopkins syndrome) show impaired pDC development and/or phenotype (Cisse et al., 2008) . Accordingly, pDCs express TCF4 whereas cDCs express Id2, which is particularly abundant in DC1 (Ginhoux et al., 2009; Jackson et al., 2011) and is required for their development (Hacker et al., 2003) . TCF4 directly activates pDC-specific gene expression program, and its loss from committed pDCs causes their spontaneous differentiation into DC1-like cells (Ghosh et al., 2010) . The in vivo counterpart of such ''defaulted'' pDCs may be represented by non-canonical CD8 + cDCs, which express many pDC-enriched genes including Tcf4 (Bar-On et al., 2010) . The activity of TCF4 is facilitated by its ETO protein cofactor CBFA2T3 (MTG16), which promotes pDC development and restricts DC1 development (Ghosh et al., 2014) . Thus, TCF4 appears as a critical determinant of the pDC versus cDC lineage specification, yet the specificity and regulation of its activity in DC development remain poorly understood.
We report that the ''long'' isoform of Tcf4 is expressed specifically in pDCs and is required for their development, contributing to the specificity of TCF4 function. We also identified a conserved distal enhancer in Tcf4 that is bound by its protein product and mediates the upregulation of Tcf4 expression during pDC lineage commitment. These results reveal the complex developmental regulation of E protein activity, which involves lineage-specific expression of E protein isoforms and feedback regulation through distal regulatory elements.
RESULTS
The Long Isoform of Tcf4 Is Expressed Specifically in pDCs To reconcile the broad expression of TCF4 with its pDC-specific activity, we analyzed the expression of its transcriptional isoforms. The FANTOM atlas of transcription start sites revealed two main transcription start sites of murine Tcf4, thereby defining two promoters ( Figures 1A and S1A ). The distal promoter gives rise to the ''long'' isoform of Tcf4 (here denoted Tcf4 L , also referred to as the ''B'' isoform [Forrest et al., 2014] ) that contains all functional domains ( Figure 1B ). The proximal promoter gives rise to a ''short'' isoform (Tcf4 S , previously also referred to as the ''A'' isoform) that lacks AD1 and ETO-binding domain (Figure 1B) . By qRT-PCR, Tcf4 S was prominently expressed in pDCs but also present in other cell types including B cells and cDCs ( Figure 1C ). In contrast, the expression of Tcf4 L was detected almost exclusively in pDCs ( Figure 1C Figure 1D ). The specificity and relative abundance of the two TCF4 isoforms were confirmed by immunoblot of pDCs derived in Flt3L-supplemented BM cultures ( Figure 1E ). Similarly, whole transcriptome sequencing (RNA-seq) of ex vivo sorted DCs (Lau et al., 2016) confirmed that the reads mapping to Tcf4 L -specific exons were present only in pDCs ( Figure 1F ). The analysis of human FANTOM atlas data revealed the same distal and proximal promoters of human TCF4 ( Figure S1B ). Furthermore, TCF4 transcripts derived from human pDCs were abundant at the distal promoter, whereas transcripts from B cells were specifically enriched at the proximal promoter ( Figure S1C) . Accordingly, the human pDC cell line Gen2.2 expressed both TCF4 isoforms, but the human B lymphoblastoid line GM12878 expressed only TCF4 S ( Figure S1D ). Thus, the main transcriptional isoforms of TCF4 and the pDC-specific expression of the long isoform appear conserved between mice and humans.
To analyze the expression of Tcf4 L in vivo at the single-cell level, we used a Tcf4 allele with a reporter cassette inserted upstream of the Tcf4 L -specific exon ( Figure 1A ). The splice acceptor in the cassette traps Tcf4 L transcript and drives the expression of bacterial LacZ gene, whose product b-galactosidase (bGal) can be visualized by flow cytometry using a fluorescent substrate. The analysis of heterozygous Tcf4
LacZ/+ reporter mice revealed homogeneous bGal expression exclusively in pDCs ( Figure 1G) Figure 1H ) typical of non-canonical CD8 + cDCs (Bar-On et al., 2010) . Collectively, these data show that Tcf4 L is expressed specifically in pDCs and reciprocally to Id2, which is abundant in canonical cDCs. Although Tcf4 L was absent from naive B cells, we observed its low expression in the germinal center (GC) B cells ( Figure S1E ). Specifically, it was detected in the CXCR4 +
CD83
À centroblast population that undergoes activation-induced deaminase (AID)-dependent somatic hypermutation and class switch recombination (Bannard et al., 2013; Victora and Nussenzweig, 2012) . Conversely, the CXCR4 À CD83 + centrocytes had lower expression of Tcf4 L but expressed detectable Id2 ( Figure S1G ). B-cellspecific deletion of TCF4 did not impair GC B cell numbers or phenotype and did not affect antibody responses or somatic hypermutation (data not shown), probably due to genetic redundancy with TCF3 (Gloury et al., 2016; Wö hner et al., 2016) . Thus, the centroblast-specific expression of TCF4 L is not required for centroblast development but is consistent with a genetically redundant function of TCF4 in these cells.
Both Tcf4 Isoforms Are Required for Optimal pDC Development In Vitro
To investigate the roles of individual Tcf4 isoforms in pDC development, we used a conditionally immortalized progenitor cell line, HoxB8-FL (Redecke et al., 2013) . Withdrawal of estrogen from these cells inactivated the immortalizing HoxB8 oncogene and induced Flt3L-dependent differentiation into pDCs and cDCs ( Figure 2A ). In this system, cDCs were CD11b + and MHC II hi , while the CD11b -MHC II -population contained B220 + Bst2 + pDCs ( Figure 2B ). We used CRISPR/ Cas9-mediated genome editing to disrupt either or both isoforms of Tcf4 in HoxB8-FL cells ( Figures S2A and S2B ). Lentiviruses encoding single guide RNA (sgRNA) to exons specific for Tcf4 L , Tcf4 S , or to a common exon were introduced into Cas9-expressing undifferentiated HoxB8-FL cells ( Figure 2C ). After selection in bulk cultures, the targeting of each isoform was confirmed by the T7 cleavage assay ( Figure S2C ) and immunoblot (data not shown), and the resulting cells were subjected to differentiation.
As expected, the deletion of both Tcf4 isoforms resulted in a profound loss of pDCs, with only few remaining cells showing low expression of pDC markers ( Figures 2D and 2E ). The deletion of either Tcf4 L or Tcf4 S allowed pDC development but caused a significant reduction of pDC fraction and absolute numbers (Figures 2D and 2E) . No significant difference was observed between the numbers of resulting pDCs after the disruption of either isoform ( Figure 2E) ; moreover, these residual pDCs had similar gene expression patterns, including the expected upregulation of cDC-enriched genes (data not shown). Finally, chromatin immunoprecipitation (ChIP-seq) analysis of TCF4 binding in cells lacking specific isoforms did not reveal major differences in binding targets (data not shown). Collectively, these data suggest that both isoforms of TCF4 have similar molecular activities and control pDC development in an additive and non-redundant fashion. Figure S1 .
Tcf4 L Is Required for Optimal pDC Development In Vivo
To test the role of the pDC-specific Tcf4 L isoform in vivo, we took advantage of the gene trap functionality of the Tcf4 LacZ allele ( Figure 1A ). Indeed, the expression of Tcf4 L was nearly abolished in Tcf4 LacZ/LacZ mice, whereas the expression of Tcf4 S was unaffected ( Figure S3A ). A specific ablation of the TCF4 L protein isoform was confirmed by immunoblot on total BM cells (Figure S3B) . Heterozygous Tcf4 LacZ/+ animals showed a minor reduction of pDC frequency in the BM and normal pDC frequency in the spleen ( Figure 3A and data not shown). Very few weaning-age homozygous Tcf4 LacZ/LacZ mice could be derived from the intercross of Tcf4
LacZ/+ parents ( Figure S3C) ; those rare mice were runted and showed abnormal behavior, likely reflecting the role of TCF4 in brain development (Flora et al., 2007) . The partial lethality and failure to thrive of Tcf4 LacZ/LacZ pDCs among total donorderived cells was significantly reduced in the BM and spleen of the resulting chimeras ( Figure 3B ). Similarly, the fraction of mature pDCs in Flt3L-supplemented cultures of Tcf4
LacZ/LacZ recipient BM was reduced ( Figure S3D ). Similar to Tcf4
pDCs, pDCs from Tcf4 LacZ/LacZ mice showed aberrant phenotype including the loss of CCR9 and CD4 and reduction of Bst2 ( Figure 3C ). Conversely, cDC markers CD11c, CD8, and (to a lesser extent) MHC class II were upregulated ( Figure 3C ), overall suggesting a ''drift'' toward the cDC fate. See also Figure S3 .
in hematopoietic stem cells (HSCs), myeloid progenitors (MPs), and common dendritic cell progenitors (CDPs), albeit lower than in pDCs ( Figure 4A ). The expression of total TCF4 protein in these progenitor populations was confirmed by intracellular staining ( Figures 4B and S4A) . By qRT-PCR, Tcf4 L and Tcf4 S transcripts were comparably expressed in progenitors, followed by Tcf4 L upregulation in the BM pDCs ( Figure S4B ). Although the CD115 -subset of common dendritic cell precursors (CDPs) was (E) The expression of TCF4 protein at the early (day 3), middle (day 5), and late (day 7) stages of DC differentiation. Shown are plots of TCF4 expression versus the markers of differentiated pDCs (Bst2, B220) or cDCs (MHC II). (F) The expression of Tcf4 isoform transcripts in the differentiating HoxB8-FL cells. Total HoxB8-FL cells at the indicated days of differentiation were analyzed by qRT-PCR using Tcf4 isoform-specific primers as in Figure 1C . Data represent transcript amount relative to Tcf4 L expression on day 0 (mean ± SD of triplicate PCR reactions). Data in (D)-(F) are representative of the original HoxB8-FL clone (Redecke et al., 2013) and two independently derived HoxB8-FL clones. See also Figure S4. reported to express as much Tcf4 as pDCs (Onai et al., 2013) , this was not observed in our analysis. Notably, cDC progenitors in the BM (pre-DCs) still expressed Tcf4 but also upregulated Id2, consistent with cDC commitment ( Figure S4C) . Thus, the expression of Tcf4 is initiated in early progenitors prior to pDC versus cDC lineage split; in particular, the expression of Tcf4 but not of Id2 by CDPs likely maintains their pDC potential.
To further resolve the temporal dynamics of Tcf4 expression during pDC development, we used the HoxB8-FL cell line. During its differentiation, CD11c-expressing DCs emerge on days 4-5 and become predominant by day 7 ( Figure 4C) . Notably, TCF4 protein expression preceded DC emergence and was already high on day 3 (Figures 4D and 4E) . By day 7, cultures contained both TCF4 + and TCF4 -cells ( Figure 4D ), with TCF4 expression enriched in B220 + Bst2 + pDCs and excluded from mature MHC II + cDCs ( Figure 4E ). qRT-PCR of total cells at each time point showed a coordinate increase of both Tcf4 isoforms on days 3-5, with a particularly notable induction of Tcf4 L ( Figure 4F ). Collectively, these data suggest that the expression of Tcf4, and particularly of the Tcf4 L isoform, precedes pDC commitment and is subsequently maintained in pDCs but downregulated in cDCs and other mature cell types.
A 3 0 Enhancer Is Required for Tcf4 Expression during pDC Development
The expression of Tcf4 prior to pDC commitment suggests that TCF4 may maintain its own expression in the developing pDCs through a putative regulatory region. The analysis of sorted primary mouse DCs for active regulatory regions by the assay for transposase-accessible chromatin (ATAC-seq) revealed several pDC-specific peaks within $1.5 Mb around the Tcf4 locus (Figure 5A) . The most prominent and specific ATAC-seq signal (two adjacent peaks) was located $150 Kb 3 0 of Tcf4, in a region that has no annotated coding genes ( Figure 5A ). The sequences corresponding to the two peaks are conserved in mammals (Figure S5A ) and contain several conserved E boxes (data not shown). Importantly, these regions correspond to the binding peaks of TCF4 in human pDC cell lines ( Figure S5A ). Comparison between DCs and other hematopoietic cell types (Shih et al., 2016) revealed that the ATAC-seq signal was low or absent in HSCs, progenitors, or B cells; it was also absent from neurons (Mo et al., 2015) , which express TCF4 ( Figure 5B ). In contrast, the promoters of both Tcf4 isoforms produced prominent ATAC-seq signal in all these cell types ( Figure 5C ).
We analyzed the 3 0 region by ChIP during the differentiation of HoxB8-FL cells. Histone modifications associated with active enhancers, including histone 3 lysine 4 monomethylation (H3K4me1) and lysine 27 acetylation (H3K27ac), were induced in this region on day 4, i.e., at the onset of pDC differentiation ( Figure 5D) . Similarly, the binding of TCF4 was massively induced at the same time point and persisted in mature pDCs. Previously published ChIP-seq analysis of BM-derived DCs (Grajales-Reyes et al., 2015) revealed the pDC-specific H3K27ac signal and binding of the co-activator p300 in this region ( Figure S5B) . Thus, the regulatory element 3 0 of Tcf4 represents a pDC-specific enhancer that becomes activated and bound by TCF4 at the onset of pDC differentiation.
To test the role of the enhancer in Tcf4 expression, we targeted it in the HoxB8-transformed cell line using the CRISPR/Cas9-based genome editing ( Figures S5C and S5D) . The resulting cells were cloned by limiting dilution and screened for the presence of the wild-type and deleted alleles. Although no homozygous deletions were found, we identified 2 out of 81 clones with a heterozygous deletion ( Figure S5E ). Upon differentiation, the two deletion-carrying clones failed to produce mature Bst2 + B220
hi pDCs (Figure 5E) . Moreover, the induction of Tcf4 expression prior to pDC differentiation on day 4 of the cultures was markedly reduced in the targeted clones ( Figure 5F ). Both Tcf4 isoforms were reduced, with the induction of Tcf4 L nearly abolished. The observed strong effects of monoallelic targeting are consistent with the haploinsufficiency of Tcf4, which is particularly evident in Flt3L-driven pDC development in culture (Cisse et al., 2008) . These data suggest that the 3 0 enhancer is required for the induction of Tcf4 in immature pDCs and for the ensuing pDC differentiation.
Tcf4 Expression and pDC Development Are Regulated by BET-Dependent Enhancers ATAC-seq and ChIP-seq analysis of transformed human pDC cell lines identified multiple regulatory elements 5 0 of TCF4, which collectively comprised a super-enhancer (Ceribelli et al., 2016) . Similarly, ATAC-seq on normal murine cells ( Figure 5A ) revealed multiple pDC-specific peaks spread across $900 Kb 5 0 of Tcf4. A more detailed analysis of this region revealed two types of ATAC-seq peaks ( Figure 6A ): those that were present in stem and progenitor cells but extinguished in pDCs (e.g., peak A) and those that were present preferentially in pDCs (e.g., peaks B and C). The pDC-specific 5 0 peaks also showed enhancer-associated chromatin marks in BM-derived pDCs ( Figure S6A ; Grajales- Reyes et al., 2015) . The reciprocal epigenetic pattern of the pDC-and progenitor-specific elements was confirmed by ChIP-qPCR analysis of HoxB8-FL cells; the progenitor-specific peak A rapidly lost activating chromatin marks upon differentiation (day 4). Conversely, pDC-specific elements B and C acquired activating chromatin marks and showed TCF4 binding by day 4 and especially in mature pDCs ( Figures 6B and S6B) . Notably, TCF4 binding at the 3 0 enhancer preceded binding at the 5 0 regulatory regions, consistent with its prominent role in the positive feedback regulation of TCF4 expression.
In transformed human pDC lines, the expression of TCF4 and activity of all its regulatory regions were dependent on bromodomain and extraterminal (BET) domain-containing proteins (Ceribelli et al., 2016) . BET proteins comprise a family of transcriptional cofactors that are particularly important for the activity of super-enhancers, and their inhibition by drugs such as JQ1 potently inhibits cell growth (Delmore et al., 2011) . Given the dependence of TCF4 expression in malignant pDCs on BET proteins, we tested whether this mechanism is also operative in normal pDC development. To circumvent the effect of JQ1 on cell growth, we used HoxB8-FL cells that cease to proliferate after the induction of differentiation. Treatment of differentiating HoxB8-FL cells with 100 nM JQ1 caused a significant reduction of pDCs, while cDC numbers were unaffected ( Figure 6C ). This was accompanied by a marked decrease of Tcf4 expression, particularly of its induction at the onset of pDC differentiation (day 4, Figure 6D ). Collectively, these data suggest that BET proteins facilitate Tcf4 expression and are required for the establishment of a TCF4-dependent positive feedback loop that facilitates pDC development.
DISCUSSION
We here report that the ''long'' transcriptional isoform of E protein TCF4 (TCF4 L ) is expressed specifically in pDCs and their progenitors, whereas the short isoform (TCF4 S ) accounts for the observed Tcf4 expression in other immune cell types. In an in vitro model of DC development, the deletion of either isoform impaired pDC development to a similar degree. Moreover, the resulting pDCs had a similar expression profile characterized by the induction of cDC-specific genes, and no difference was found between the binding targets of specific isoforms (data not shown). Therefore, the two transcriptional isoforms of Tcf4 (E) The differentiation output of HoxB8-FL clones with heterozygous enhancer deletion (Del-1 and -2) and a control non-targeted clone. Shown are staining plots of day 7 differentiated cultures gated on the CD11b À MHC II À non-cDC population, with the Bst2 + B220 + mature pDCs highlighted. Representative of three independent differentiation experiments.
(F) The expression of Tcf4 isoform transcripts during the differentiation of enhancer-targeted clones shown above. Total cultures on days 0, 4, or 7 of differentiation were analyzed by qRT-PCR using Tcf4 isoform-specific primers as in Figure 1C . Data represent transcript amounts relative to Tcf4 L expression on day 0 (mean ± SD of triplicate PCR reactions; representative of two differentiation experiments). See also Figure S5 .
may be functionally overlapping and contribute to pDC development in an additive manner. These results were confirmed in vivo for Tcf4 L , whose deletion did not abolish the development of pDCs but led to their reduced numbers and impaired phenotype.
This isoform may be particularly important for pDC development rather than maintenance, because its deletion had a stronger impact on pDCs in the BM than in the spleen; in contrast, haplodeficiency for total Tcf4 has a minor effect on BM pDCs but (D) The expression of Tcf4 isoform transcripts in JQ1-treated HoxB8-FL cells. Total HoxB8-FL cells at the indicated days of differentiation were analyzed by qRT-PCR using Tcf4 isoform-specific primers as in Figure 1C . Data represent transcript amounts relative to Tcf4 L expression on day 0 (mean ± SD of triplicate PCR reactions). Representative of two experiments. See also Figure S6 . strongly affects their peripheral maintenance and functionality (Cisse et al., 2008; Ghosh et al., 2010) . Overall, the combination of a broadly expressed and a lineage-specific transcriptional isoform facilitate and fine-tune the role of TCF4 in pDC specification and maintenance. The loss of TCF4 L reduced pDC numbers and caused phenotypic changes characteristic of cDC differentiation, resembling the reduction of total TCF4 or of its cofactor Mtg16. Notably, the loss of total TCF4 or of Mtg16 abolished the development of non-canonical Id2 lo CD8 + cDCs (Bar-On et al., 2010; Ghosh et al., 2014) , whereas the deletion of TCF4 L enhanced it. These results further suggest that the non-canonical CD8 + cDCs are ''by-products'' of pDC development, originating from pDCs that failed to accrue sufficient TCF4 expression (Reizis et al., 2011) . Thus, strong reduction of net TCF4 activity (e.g., in TCF4 or Mtg16 deficiency) impairs both pDCs and non-canonical cDCs, whereas moderate reduction (e.g., in TCF4 L deficiency) ''shunts'' pDCs toward the non-canonical cDCs. This shunt apparently occurs early in developing pDCs rather than in the periphery, because pDC reduction is already prominent in the BM. The CCR9 À pDC precursor that retains the cDC potential (Schlitzer et al., 2011) represents a likely stage of the bifurcation between pDCs and non-canonical cDCs. The proposed model reconciles our results with previous observations and suggests that the TCF4 L isoform is particularly important for cell fate stabilization in immature pDCs. The key role of TCF4 in pDC lineage specification begs the question of upstream signal(s) that induce its expression in pDCs. We here report that TCF4, particularly its pDC-specific long isoform, is expressed in hematopoietic progenitors and is further induced in pDCs but silenced in other cell types. Similarly, in a ''time-controlled'' HoxB8-FL cell line model, TCF4 was induced in most cells and then ''resolved'' at the pDC versus cDC bifurcation. The expression of TCF4 but not of its inhibitor Id2 is particularly notable in CDPs, supporting the role of this population as a major source of pDCs. This observation also explains the early expression of pDC-specific genes in CDPs (Miller et al., 2012) , which probably reflects their pDC potential rather than actual commitment. We have previously described a negative feedback loop whereby TCF4 and its cofactor Mtg16 repress the expression of Id2 (Ghosh et al., 2014) . Conversely, the increase of TCF4 expression from intermediate in progenitors to high in pDCs can be best explained by a positive feedback regulation by TCF4 and its target transcription factors such as Bcl11a and SpiB (Ghosh et al., 2010; Ippolito et al., 2014; Nagasawa et al., 2008) . Such E protein-dependent positive and negative feedback loops represent a robust ''built-in'' mechanism of DC diversification in the absence of specific inducers.
The postulated cell-intrinsic upregulation of TCF4 in pDCs implies a cis-regulatory element that would enhance the expression of both TCF4 isoforms in response to TCF4 itself. We have identified a conserved pDC-specific enhancer 3 0 of Tcf4 that is prominently bound by TCF4 in human and murine cultured pDCs. During HoxB8-FL differentiation, activated chromatin marks and TCF4 binding in the enhancer coincided with the induction of Tcf4 expression prior to the emergence of mature pDCs. Finally, monoallelic deletion of this element reduced the induction of Tcf4 during pDC differentiation and the output of mature pDCs in vitro. Thus, Tcf4 expression in pDC lineage specification is controlled by the 3 0 lineage-specific enhancer through a TCF4-dependent positive feedback loop.
In addition to the 3 0 enhancer, multiple elements in the Tcf4 5 0 region showed dynamic changes during pDC differentiation. Some of these elements appeared active in stem cells and progenitors but silent in pDCs, suggesting that they might regulate the initial Tcf4 expression prior to DC development. Other 5 0 elements became active specifically in pDCs; these elements also bound TCF4 and therefore may play a role in its feedback regulation. Notably, the 3 0 enhancer showed an earlier activation and stronger TCF4 binding during pDC development, consistent with its major non-redundant role in the process. Thus, distal 5 0 and 3 0 regulatory elements appear to drive TCF4 expression, and their combinations with the respective promoters yield broader (for TCF4 S ) or pDC-specific (for TCF4 L ) expression patterns. In cultured human pDC lymphoma cell lines, the activity of all distal regulatory elements of TCF4 is controlled by BET domain proteins and is inhibited by BET inhibitor JQ1 (Ceribelli et al., 2016) . Accordingly, Tcf4 expression during pDC differentiation was also inhibited by JQ1, extending this mechanism to normal DC development. The preferential sensitivity of pDC development to BET inhibition further emphasizes the active nature of pDC development, which is driven by a hierarchy of regulatory elements controlling Tcf4 expression. In contrast, cDC differentiation may represent a ''default'' pathway in the absence of dominant E protein activity (Ghosh et al., 2010) .
In conclusion, we describe tissue-specific isoform usage and feedback regulation of E protein TCF4 in a prototypical lineage specification event, the choice between pDC and cDC lineages. The positive feedback mechanism of TCF4 regulation helps explain essential features of the pDC versus cDC lineage choice, including its apparent cell-intrinsic nature; resolution from a TCF4-intermediate progenitor state into TCF4-expressing pDCs and Id2-expressing cDCs; and enhanced DC1 development at the expense of pDCs upon the net reduction of E protein activity (Ghosh et al., 2014; Scott et al., 2016) . Similar mechanisms involving E proteins and their antagonists are probably operational in other immune cell lineages such as T and B lymphocytes, as well as in other tissues such as the brain.
EXPERIMENTAL PROCEDURES Animals
All animal experiments were performed according to the investigator's protocol approved by the Institutional Animal Care and Use Committee. The targeted Tcf4 reporter allele (Tcf4 tm1a(EUCOMM)Wtsi ) has been generated as part of the Mouse Knockout Project (KOMP). Embryonic stem cells (JM8.F6 line, C57BL/6) were injected into C57BL/6 blastocysts at the KOMP/Mouse Biology Program at the University of California, San Diego, and the resulting chimeras were crossed to C57BL/6 mice to generate Tcf4
LacZ mice on pure C57BL/6 background. 
Cell Culture
Murine progenitor HoxB8-FL cell line was derived and cultured as described (Redecke et al., 2013) . In brief, the cells were grown in RPMI supplemented with 10% FCS, 10% supernatant from the Flt3L-producing B16 cell line, and 10 mM b-estradiol. The cells were induced to differentiate into DCs by washing and replating in the same medium without b-estradiol. For pDC development in vitro, total BM cells (2 3 10 6 /mL) were cultured for 7 days with 100 ng/mL recombinant human Flt3L (PeproTech). For protein analysis, pDCs were enriched by magnetic sorting (Miltenyi Biotech) for B220 + cells. For BET-protein inhibition, HoxB8-FL cells were differentiated in the presence of 100 nM JQ1 (SigmaAldrich) dissolved in DMSO or in DMSO alone as a control.
Genome Editing in HoxB8-FL Cells
The Tcf4 isoforms were targeted using the CRISPR/Cas9 approach with sgRNAs to exons specific for either isoform or to a common exon as a control. The 3 0 enhancer element was targeted using the short guiding RNAs to DNA elements flanking the region. Details of the targeting are described in Supplemental Experimental Procedures.
Cell Analysis
Single-cell suspension of splenocytes or BM cells were subjected to red blood cell lysis, washed, and then stained for multicolor analysis with the indicated fluorochrome-conjugated antibodies (BD Biosciences or eBioscience). The samples were acquired on an LSRII flow cytometer or sorted on FACSAria II flow sorter (BD Biosciences) and analyzed with FlowJo software (TreeStar). The pDCs were defined as B220 + CD11c lo Bst2 + ; cDCs were defined as B220 -CD11c hi and further sub-divided into subsets as indicated. For progenitor analysis, BM cells were stained with a cocktail of antibodies to lineage markers (CD3, NK1.1, CD19, CD11b, Gr1) and the DC marker CD11c, unless it was used in a separate fluorescence channel. Id2 expression was detected by surface staining with a fluorochrome-conjugated antibody specific to human CD5 (clone UCHT2). To analyze LacZ expression, cells were resuspended in HBSS with 1 mM HEPES and 2% FBS, incubated for 20 min at 37 C, mixed with pre-warmed fluorescein di-b-D-galactopyranoside (FDG, Sigma Aldrich) in a hypotonic solution for 1 min, placed on ice, and washed with ice-cold buffer. Endogenous b-gal activity from lysosomes was inhibited by chloroquine diphosphate. After FDG loading, cells were stained for surface markers and analyzed by flow cytometry. For intracellular TCF4 staining, cells were stained for surface markers, fixed/ permeabilized with the intracellular fixation and permeabilization buffer kit (eBioscience) for 1 hr at 4 C, and incubated with 2% mouse serum for 15 min. Cells were stained for 1 hr at room temperature with control rabbit IgG or with a rabbit mAb to TCF4 (Ceribelli et al., 2016) . The cells were then washed, incubated with PE-conjugated anti-rabbit IgG (Jackson Immunoresearch), and analyzed by flow cytometry.
Gene Expression Analysis RNA from total or sorted cell samples was isolated using TRIzol reagent (Life Technologies), reverse transcribed (SuperScript III; Life Technologies), and assayed by SYBR Green-based real-time PCR using primers listed in Supplemental Experimental Procedures. The expression of Tcf4 and Id2 were normalized to that of housekeeping gene Actb and quantified using the DDC T method. For protein analysis, cell pellets were lysed with a nuclear lysis buffer (1% SDS, 150 mM Tris-HCl [pH 8.25], 10 mM EDTA), sonicated briefly to facilitate pipetting, and boiled for 10 min in the presence of 1% SDS loading buffer. Lysates from equal cell numbers were analyzed by SDS-PAGE followed by western blotting with antibodies to TCF4 or to tubulin as a loading control.
Chromatin Analysis
Visualization and analysis of existing ATAC-seq and ChIP-seq data are described in Supplemental Experimental Procedures. Chromatin immunoprecipitation in HoxB-FL cells was performed as previously described (Ghosh et al., 2014) . In brief, 3 3 10 6 cells were fixed for 5 min using the truChIP High Cell Chromatin Shearing Kit with SDS Shearing Buffer (Covaris) according to manufacturer's protocol. The fixed nuclei were sheared using the Covaris LE220 ultrasonicator for 6 min. Sheared chromatin was incubated overnight at 4 C with magnetic Protein A beads pre-coated with Abs to TCF4, H3K4me1 (Abcam), or H3K27ac (Abcam). The DNA was eluted from beads by incubating at 65 C for 15 min, incubated overnight at 65 C to reverse crosslinks, purified, and used for qPCR using primers listed in Supplemental Experimental Procedures. A fixed amount of total chromatin input was used as a control. Percent input was calculated using 100*2^(adjusted input À C T (IP)), where adjusted input equals C T (input) À log 2 (dilution factor). Fold enrichment was calculated using % input (region of interest) divided by % input (control region).
Statistical Analysis
Statistical significance was estimated by nonparametric Mann-Whitney test except in Figure 6C , in which Wilcoxon matched-pairs signed-rank test was used. 
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